Carl Zeiss Meditec


Microsurgery leads the pack in Q4

07/12/18 -"although sales in the Ophthalmic Devices segment missed expectations in Q4, the fourth consecutive quarter of double-digit growth in the Microsurgery division ensured that FY17/18 revenue targets ..."

Pages
51
Language
English
Published on
07/12/18
You may also be interested by these reports :
09/12/18
Contrary to FMC, Fresenius did not cancel its FY guidance for 2018 despite FMC’s lower contribution. In fact, Fresenius clearly flagged a more ...

09/12/18
In order to manage investors’ expectations for FMC’s performance in 2019, there is a hidden profit warning for 2018. Management expects 2018 sales to ...

07/12/18
although sales in the Ophthalmic Devices segment missed expectations in Q4, the fourth consecutive quarter of double-digit growth in the Microsurgery ...

03/12/18
Laggards and leaders While the broader AV universe was down 0.85% in November 2018, the MedTech sector plummeted 3.57% during the month. Sartorius ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO